Brief: Axcella Therapeutics Announces FDA Fast Track Designation For Axa1125 In Nash
14/02/2022 14:44
Feb 14 (Reuters) - Axcella Health Inc AXLA.O :
* AXCELLA THERAPEUTICS ANNOUNCES FDA FAST TRACK DESIGNATION
FOR
AXA1125 IN NASH
* AXCELLA HEALTH INC - EMMPACT PHASE 2B CLINICAL TRIAL
ENROLLING
WELL, WITH INTERIM DATA EXPECTED IN MID-2022
Source text for Eikon: ID:nBw21sp8Fa
Further company coverage: AXLA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Axcella Health
See all newsAxcella Health Inc expected to post a loss of $1.25 a share - Earnings Preview
Brief: Axcella Health Inc- On Oct 4, Co Received Notice From Nasdaq That Co Had Regained Compliance With Nasdaq
Brief: Axcella Announces Reverse Stock Split Effective September 19, 2023
U.S. STOCKS ON THE MOVE-PDD Holdings, Catalent, Best Buy
Brief: Axcella Granted Patent For Long Covid Fatigue Treatment